Refining Vancomycin Use in Early CDI - Top-Institutions - MDSpire

Refining Vancomycin Use in Early CDI

A modified dosing approach could reshape recurrence prevention strategies.

  • By

  • Julia Cipriano, MS, CMPP

  • March 4, 2026

  • 2 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    McGill University Health Centre
    McGill University Health Centre

    Montreal, Quebec

    Key Differentiators

    • Infectious Diseases
    • Gastroenterology
    • Clinical Research

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Infectious Diseases
    • Gastroenterology
    • Clinical Trials

  • #3

    Massachusetts General Hospital / Harvard Medical School
    Massachusetts General Hospital / Harvard Medical School

    Boston, Massachusetts

    Key Differentiators

    • Infectious Diseases
    • Gastroenterology
    • Microbiology

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, California

    Key Differentiators

    • Infectious Diseases
    • Gastroenterology
    • Clinical Research

Original Source(s)

Refining Vancomycin Use in Early CDI

  • by Julia Cipriano, MS, CMPP

  • March 4, 2026

Related Content

Post-pandemic resurgence of Mycoplasma pneumoniae and its emerging link with Rhinovirus in children

Antibiotics May Not Help Mild COVID

A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.

Amputation Rates Rose in Opioid-Related Hospitalizations

National inpatient analysis found steeper increases in amputations during opioid-related hospitalizations, particularly in the Northeast and West.